Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Galmed Pharmaceuticals Ltd - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
GLMD
Nasdaq
8731
https://www.galmedpharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Galmed Pharmaceuticals Ltd
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis
- Mar 15th, 2024 1:00 pm
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
- Nov 21st, 2023 12:32 pm
Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study
- Nov 20th, 2023 9:05 pm
Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis
- Sep 26th, 2023 12:30 pm
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
- Sep 22nd, 2023 8:05 pm
Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering
- Jul 14th, 2023 1:20 pm
Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC
- Jul 10th, 2023 12:00 pm
Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments
- Jun 1st, 2023 12:00 pm
Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)
- May 9th, 2023 11:00 am
Galmed Pharmaceuticals forms a Strategic Partnership with OnKai
- May 4th, 2023 8:00 pm
Scroll